Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Rapt Therapeutics (RAPT) had Free Cash Flow per Share of $-2.05 for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-129.87M |
|
-- |
|
-- |
|
$136.10M |
|
$-136.10M |
|
$6.24M |
|
$-129.87M |
|
$-129.87M |
|
$-129.87M |
|
$-129.87M |
|
$-129.87M |
|
$-129.87M |
|
$-136.10M |
|
$-137.71M |
|
40.76M |
|
40.76M |
|
$-3.19 |
|
$-3.19 |
|
| Balance Sheet Financials | |
$235.24M |
|
$1.37M |
|
$5.09M |
|
$240.32M |
|
$48.35M |
|
-- |
|
$2.07M |
|
$50.42M |
|
$189.90M |
|
$189.90M |
|
$189.90M |
|
132.01M |
|
| Cash Flow Statement Financials | |
$-83.30M |
|
$52.70M |
|
$152.85M |
|
$47.48M |
|
$169.74M |
|
$122.26M |
|
$19.93M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.87 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-83.42M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-68.38% |
|
-68.38% |
|
-54.04% |
|
-68.38% |
|
$1.44 |
|
|
Free Cash Flow per Share |
$-2.05 |
$-2.04 |
|